DiaMedica director granted 40,412 stock options

DiaMedica Therapeutics Inc. director Richard Kuntz reported a grant of stock options.

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. director Richard Kuntz reported a grant of stock options. He received options covering 40,412 Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036. These options are scheduled to vest in four equal quarterly installments, and following this grant he holds 40,412 derivative securities directly.

Insider Trade Summary

Grant/Award: 40,412 shares

Grant/Award 1 txn

Insider Kuntz Richard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,412	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,412 contracts (Direct)

Footnotes (1)

1. F1. Scheduled to vest in four equal quarterly installments.

Key Figures

Option grant size: 40,412 options Exercise price: $5.84 per share Underlying shares: 40,412 shares +3 more

6 metrics

Option grant size 40,412 options Stock Option (right to buy) granted to director

Exercise price $5.84 per share Exercise price for underlying Voting Common Shares

Underlying shares 40,412 shares Voting Common Shares underlying the option grant

Expiration date June 1, 2036 Option expiration for granted stock options

Post-grant derivative holdings 40,412 securities Total derivative securities held after transaction

Vesting schedule Four equal quarterly installments Footnote indicates quarterly vesting pattern

Key Terms

Stock Option (right to buy), exercise price, Voting Common Shares, vest in four equal quarterly installments

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price of 5.8400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Voting Common Shares financial

"underlying_security_title: Voting Common Shares"

vest in four equal quarterly installments financial

"Scheduled to vest in four equal quarterly installments."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DiaMedica Therapeutics (DMAC) report for Richard Kuntz?

DiaMedica Therapeutics reported that director Richard Kuntz received a grant of stock options for 40,412 Voting Common Shares. The options are derivative securities giving him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Richard Kuntz’s new DiaMedica (DMAC) stock options?

The granted stock options to Richard Kuntz have an exercise price of $5.84 per share. This means he can buy DiaMedica Voting Common Shares at $5.84 regardless of the market price when he chooses to exercise, subject to vesting.

How many DiaMedica (DMAC) shares are covered by Richard Kuntz’s option grant?

The option grant to Richard Kuntz covers 40,412 underlying Voting Common Shares. These options give him the right to purchase that number of shares once they vest and before the stated expiration date, assuming he exercises them.

When do Richard Kuntz’s DiaMedica (DMAC) stock options vest?

The stock options granted to Richard Kuntz are scheduled to vest in four equal quarterly installments. This means the total 40,412 options become exercisable in stages over four quarters, rather than all at once on the grant date.

When do Richard Kuntz’s DiaMedica (DMAC) stock options expire?

Richard Kuntz’s stock options are set to expire on June 1, 2036. He must exercise the vested portions of the 40,412 options before this expiration date, or the right to purchase those shares will lapse.

How many derivative securities does Richard Kuntz hold in DiaMedica (DMAC) after this filing?

Following the reported grant, Richard Kuntz directly holds 40,412 derivative securities in the form of stock options. Each option corresponds to one underlying Voting Common Share, subject to vesting and the $5.84 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kuntz Richard

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		40,412		(1)	06/01/2036	Voting Common Shares	40,412	$0	40,412	D

Explanation of Responses:

1. Scheduled to vest in four equal quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)